## 10/589832

## IAP11 Rec'd PCT/PTO 17 AUG 2006

Patent
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Toshiyuki Takahashi	
Int'l Appln. No. :	PCT/JP2005/002948	
Int'l Date Filed :	17 February 2005 (02	2/17/2005)
Serial No. :	(To be assigned)	Case No.: BY0037P
Filed :	August 17, 2006	
For :	NITROGENOUS FU DERIVATIVE	JSED HETEROAROMATIC RING
Commissioner for Alexandria, Virg	or Patents ginia 22313-1450	••••••

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

DATE OF DEPOSIT

DATE OF DEPOSIT

EVALUATION

DEPOSIT

EVALUATION

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL

SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSED TO

COMMISSIONER FOR PATENTS, PO. BOX 1450,
ALEXANDRIA, VIRGINIA 22813-1450.

MAILED BY

DATE

18/589832

Serial No.: Case No.: To be assigned BY0037P

Page

2

## IAP11 Rec'd PCT/PTO 17 AUG 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

V Fric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: August 17, 2006

-	9
5	

Substitute for form 1449A/PTO		Application NumbiAP11 Rec'd PCT/PTO 17 AUG 2000			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	1100 01 0111 10
			PLICANT	First Named Inventor	Toshiyuki Takahashi
(una sa manu ali anta na manana)				Group Art Unit	
(use as many sheets as necessary)			iecessury)	Examiner Name	
Sheet	1	of	2	Attorney Docket Number	BY0037P

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document  Number Kind Code (if known)			Date of Publication of Cited Document MM-DD-YYYY		
		4810705		Sanofi	03/07/1989		
		5011835		Merrell Dow Pharmaceuticals Inc.	04/30/1991		
			_				
·							

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Office Number Code		Kind Name of Patentee		Date of Publication of Cited Document MM-DD-YYYY	
		EP 1243	3271		Takeda Chemical Industries, Ltd.	09/25/2002	
			<del></del>				
		<del>                                     </del>					
				-			
Examine Signatur	er re				Date Considered		

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IAI	Approved for use through 7/31/2006. OMB 0651-0031  Approv
D G	COMPLETE IF KNOWN

Substitute for form 1449B/PTO				COMPLETE IF KNOWN		
_	INFORMATION	DIS	CLOSURE	Application Number		
STATEMENT BY APPLICANT			DI ICANIT	Filing Date		
			PLICANI	First Named Inventor	Toshiyuki Takahashi	
			,	Group Art Unit		
(use as many sheets as necessary)			necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	BY0037P	

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
		Razvi, Mehboob et al., Synthesis and biological activity of 3,6-diaryl-1,2,4-triazolo[3, 4-a]phthalazines, Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, vol. 28B, No. 11, pages 987 to 989, 1989.						
		Lieberman, Daniel F. et al., A new and improved synthesis of 6-aryl -1,2,4-triazolo[4,3-b]pyridazines, Journal of Heterocyclic Chemistry, vol. 25, No. 3, pages 827 to 830, 1988.						

Examiner Signature	Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form \* IDS Form\* (IDS Folder), Merck & Co., Inc., -7/12/2005